Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron
S Wang, H Sun, Y Zhang, L Yuan, Y Wang, T Zhang… - Cell reports, 2022 - cell.com
The rapidly spreading Omicron variant is highly resistant to vaccines, convalescent sera,
and neutralizing antibodies (nAbs), highlighting the urgent need for potent therapeutic nAbs …
and neutralizing antibodies (nAbs), highlighting the urgent need for potent therapeutic nAbs …
Monoclonal antibodies for malaria prevention
M Aleshnick, M Florez-Cuadros, T Martinson… - Molecular Therapy, 2022 - cell.com
Monoclonal antibodies are highly specific proteins that are cloned from a single B cell and
bind to a single epitope on a pathogen. These laboratory-made molecules can serve as …
bind to a single epitope on a pathogen. These laboratory-made molecules can serve as …
Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins
SARS-CoV-2 infection or vaccination produces neutralizing antibody responses that
contribute to better clinical outcomes. The receptor-binding domain (RBD) and the N …
contribute to better clinical outcomes. The receptor-binding domain (RBD) and the N …
Targeting the spike receptor binding domain class V Cryptic Epitope by an antibody with Pan-Sarbecovirus activity
Novel therapeutic monoclonal antibodies (MAbs) must accommodate comprehensive
breadth of activity against diverse sarbecoviruses and high neutralization potency to …
breadth of activity against diverse sarbecoviruses and high neutralization potency to …
A SARS-CoV-2 spike ferritin nanoparticle vaccine is protective and promotes a strong immunological response in the cynomolgus macaque coronavirus disease 2019 …
SC Johnston, KM Ricks, I Lakhal-Naouar, A Jay… - Vaccines, 2022 - mdpi.com
The COVID-19 pandemic has had a staggering impact on social, economic, and public
health systems worldwide. Vaccine development and mobilization against SARS-CoV-2 (the …
health systems worldwide. Vaccine development and mobilization against SARS-CoV-2 (the …
Two antibodies show broad, synergistic neutralization against SARS-CoV-2 variants by inducing conformational change within the RBD
H Sun, T Deng, Y Zhang, Y Lin, Y Jiang, Y Jiang… - Protein & …, 2024 - academic.oup.com
Continual evolution of the severe acute respiratory syndrome coronavirus (SARS-CoV-2)
virus has allowed for its gradual evasion of neutralizing antibodies (nAbs) produced in …
virus has allowed for its gradual evasion of neutralizing antibodies (nAbs) produced in …
Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain
RS Sankhala, V Dussupt, WH Chen, H Bai, EJ Martinez… - Structure, 2024 - cell.com
Given the continuous emergence of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) variants of concern (VoCs), immunotherapeutics that target conserved …
(SARS-CoV-2) variants of concern (VoCs), immunotherapeutics that target conserved …
Evaluation of antibody-dependent fc-mediated viral entry, as compared with neutralization, in sars-Cov-2 infection
L Wieczorek, M Zemil, M Merbah, V Dussupt… - Frontiers in …, 2022 - frontiersin.org
Fc-mediated virus entry has been observed for many viruses, but the characterization of this
activity in convalescent plasma against SARS-CoV-2 Variants of Concern (VOC) is …
activity in convalescent plasma against SARS-CoV-2 Variants of Concern (VOC) is …
[HTML][HTML] SARS-CoV-2 pandemics: an update of CRISPR in diagnosis and host–virus interaction studies
Abstract Since December 2019, the Coronavirus disease 2019 (COVID-19) outbreak caused
by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has spread rapidly …
by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has spread rapidly …
[HTML][HTML] Conserved neutralizing epitopes on the N-terminal domain of variant SARS-CoV-2 spike proteins
Z Wang, F Muecksch, A Cho, C Gaebler, HH Hoffmann… - bioRxiv, 2022 - ncbi.nlm.nih.gov
SARS-CoV-2 infection or vaccination produces neutralizing antibody responses that
contribute to better clinical outcomes. The receptor binding domain (RBD) and the N …
contribute to better clinical outcomes. The receptor binding domain (RBD) and the N …